开云app官网登录入口网页版-官方正版

#新型抗凝药#

11篇内容 | 849人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1998533, encodeId=5306199853396, content=<a href='/topic/show?id=efbf5822950' target=_blank style='color:#2F92EE;'>#新型抗凝药#</a>, objectTitle=ESC 2022：新型抗凝药Asundexian可降低复发性缺血性卒中和TIA风险, objectType=article, longId=737357, objectId=c23ee3735770, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c23ee3735770, replyNumber=0, likeNumber=0, createdTime=2023-04-01, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c23ee3735770, moduleTitle=ESC 2022：新型抗凝药Asundexian可降低复发性缺血性卒中和TIA风险, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c23ee3735770)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998531, encodeId=d965199853182, content=<a href='/topic/show?id=efbf5822950' target=_blank style='color:#2F92EE;'>#新型抗凝药#</a>, objectTitle=新型抗凝药asundexian启动 III 期临床研究，评估其在房颤和卒中或短暂性脑缺血高危患者中的疗效, objectType=article, longId=737230, objectId=9f1ae3723033, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f1ae3723033, replyNumber=0, likeNumber=129, createdTime=2023-05-17, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f1ae3723033, moduleTitle=新型抗凝药asundexian启动 III 期临床研究，评估其在房颤和卒中或短暂性脑缺血高危患者中的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9f1ae3723033)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998532, encodeId=d14f19985324c, content=<a href='/topic/show?id=efbf5822950' target=_blank style='color:#2F92EE;'>#新型抗凝药#</a>, objectTitle=ESC 2022：新型抗凝药Asundexian在心肌梗死后患者中显示出良好前景（PACIFIC研究）, objectType=article, longId=737322, objectId=ac7de3732290, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac7de3732290, replyNumber=0, likeNumber=87, createdTime=2023-07-15, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac7de3732290, moduleTitle=ESC 2022：新型抗凝药Asundexian在心肌梗死后患者中显示出良好前景（PACIFIC研究）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ac7de3732290)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998530, encodeId=34b719985308b, content=<a href='/topic/show?id=efbf5822950' target=_blank style='color:#2F92EE;'>#新型抗凝药#</a>, objectTitle=JACC：新型抗凝药利伐沙班减少外周动脉血管重建后的首次及总缺血事件, objectType=article, longId=214764, objectId=b2bf214e640e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2bf214e640e, replyNumber=0, likeNumber=105, createdTime=2022-02-15, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2bf214e640e, moduleTitle=JACC：新型抗凝药利伐沙班减少外周动脉血管重建后的首次及总缺血事件, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b2bf214e640e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998529, encodeId=30dd1998529bf, content=<a href='/topic/show?id=efbf5822950' target=_blank style='color:#2F92EE;'>#新型抗凝药#</a>, objectTitle=对于非瓣膜性房颤使用新型抗凝药物的用量如何确定？, objectType=article, longId=214673, objectId=3ca32146e3e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ca32146e3e5, replyNumber=0, likeNumber=76, createdTime=2022-05-07, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ca32146e3e5, moduleTitle=对于非瓣膜性房颤使用新型抗凝药物的用量如何确定？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3ca32146e3e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998528, encodeId=5e16199852824, content=<a href='/topic/show?id=efbf5822950' target=_blank style='color:#2F92EE;'>#新型抗凝药#</a>, objectTitle=Ann Intern Med：45项研究Meta分析：早期慢性肾病患者应优选新型抗凝药物, objectType=article, longId=175656, objectId=034c1e56563f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=034c1e56563f, replyNumber=0, likeNumber=74, createdTime=2020-04-14, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=034c1e56563f, moduleTitle=Ann Intern Med：45项研究Meta分析：早期慢性肾病患者应优选新型抗凝药物, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=034c1e56563f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998527, encodeId=e5cf199852e3f, content=<a href='/topic/show?id=efbf5822950' target=_blank style='color:#2F92EE;'>#新型抗凝药#</a>, objectTitle=Circulation：冠脉介入后房颤抗栓白皮书：**双联抗栓，新型抗凝药物优先, objectType=article, longId=146318, objectId=4c2714631884, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c2714631884, replyNumber=0, likeNumber=69, createdTime=2018-10-25, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c2714631884, moduleTitle=Circulation：冠脉介入后房颤抗栓白皮书：**双联抗栓，新型抗凝药物优先, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4c2714631884)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998526, encodeId=aaa4199852630, content=<a href='/topic/show?id=efbf5822950' target=_blank style='color:#2F92EE;'>#新型抗凝药#</a>, objectTitle=OCC 2016：指南中新型抗凝药物的应用原则, objectType=article, longId=69560, objectId=c78a695605c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c78a695605c, replyNumber=0, likeNumber=65, createdTime=2017-02-01, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c78a695605c, moduleTitle=OCC 2016：指南中新型抗凝药物的应用原则, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c78a695605c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998525, encodeId=f94919985250b, content=<a href='/topic/show?id=efbf5822950' target=_blank style='color:#2F92EE;'>#新型抗凝药#</a>, objectTitle=[OCC2013]新型抗凝药物在房颤治疗中的应用与评价, objectType=article, longId=19263, objectId=df521926397, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df521926397, replyNumber=0, likeNumber=79, createdTime=2013-08-14, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df521926397, moduleTitle=[OCC2013]新型抗凝药物在房颤治疗中的应用与评价, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=df521926397)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998524, encodeId=f9f61998524bd, content=<a href='/topic/show?id=efbf5822950' target=_blank style='color:#2F92EE;'>#新型抗凝药#</a>, objectTitle=AIM：荟萃分析发现新型抗凝药对急性冠脉综合征（ACS）几乎没用, objectType=article, longId=10045, objectId=053710045ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=053710045ad, replyNumber=0, likeNumber=65, createdTime=2013-09-10, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=053710045ad, moduleTitle=AIM：荟萃分析发现新型抗凝药对急性冠脉综合征（ACS）几乎没用, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=053710045ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1998523, encodeId=b28f1998523bc, content=<a href='/topic/show?id=efbf5822950' target=_blank style='color:#2F92EE;'>#新型抗凝药#</a>, objectTitle=心房颤动抗凝治疗进展——新型抗凝药物, objectType=article, longId=6647, objectId=f365664e2e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f365664e2e, replyNumber=0, likeNumber=72, createdTime=2012-10-02, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f365664e2e, moduleTitle=心房颤动抗凝治疗进展——新型抗凝药物, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f365664e2e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

新型抗凝药

2020-05-29

zhu_jun9837 (审核中...)

前往app查看评论内容

#新型抗凝药#

ESC 2022：新型抗凝药Asundexian可降低复发性缺血性卒中和TIA风险

2023-04-01

zhu_jun9837 (审核中...)

前往app查看评论内容

#新型抗凝药#

新型抗凝药asundexian启动 III 期临床研究，评估其在房颤和卒中或短暂性脑缺血高危患者中的疗效

2023-05-17

zhu_jun9837 (审核中...)

前往app查看评论内容

#新型抗凝药#

ESC 2022：新型抗凝药Asundexian在心肌梗死后患者中显示出良好前景（PACIFIC研究）

2023-07-15

zhu_jun9837 (审核中...)

前往app查看评论内容

#新型抗凝药#

JACC：新型抗凝药利伐沙班减少外周动脉血管重建后的首次及总缺血事件

2022-02-15

zhu_jun9837 (审核中...)

前往app查看评论内容

#新型抗凝药#

对于非瓣膜性房颤使用新型抗凝药物的用量如何确定？

2022-05-07

zhu_jun9837 (审核中...)

前往app查看评论内容

#新型抗凝药#

Ann Intern Med：45项研究Meta分析：早期慢性肾病患者应优选新型抗凝药物

2020-04-14

zhu_jun9837 (审核中...)

前往app查看评论内容

#新型抗凝药#

Circulation：冠脉介入后房颤抗栓白皮书：**双联抗栓，新型抗凝药物优先

2018-10-25

zhu_jun9837 (审核中...)

前往app查看评论内容

#新型抗凝药#

OCC 2016：指南中新型抗凝药物的应用原则

2017-02-01

zhu_jun9837 (审核中...)

前往app查看评论内容

#新型抗凝药#

[OCC2013]新型抗凝药物在房颤治疗中的应用与评价

2013-08-14

zhu_jun9837 (审核中...)

前往app查看评论内容

#新型抗凝药#

AIM：荟萃分析发现新型抗凝药对急性冠脉综合征（ACS）几乎没用

2013-09-10

zhu_jun9837 (审核中...)

前往app查看评论内容

#新型抗凝药#

心房颤动抗凝治疗进展——新型抗凝药物

2012-10-02

科室
- - 订阅+
  - 更多科室
工具
服务